Key result
Rhein reduced urinary albumin excretion after 8 weeks and significantly decreased extracellular matrix levels in db/db mice with diabetic nephropathy, showing more powerful renal protection than simvastatin.
Why the study?
Does rhein improve renal lesions and dyslipidemia compared to simvastatin in db/db mice with diabetic nephropathy?
Population
db/db mice with diabetic nephropathy
Comparison
Rhein vs Simvastatin
Design
Preclinical
Follow-up
12 weeks
Authors
Loading...
Rhein’s renal effects in mice warrant human trials; leaves open translation to clinical use over simvastatin.
Does rhein improve renal lesions and dyslipidemia compared to simvastatin in db/db mice with diabetic nephropathy?
Rhein ameliorates diabetic nephropathy progression and dyslipidemia in a mouse model, showing superior renal protective effects compared to simvastatin.
Gao et al. (2009) studied Diabetic nephropathy. Rhein vs. Simvastatin was evaluated on Urinary albumin excretion (UAE) and extracellular matrix (ECM) levels. Rhein reduced urinary albumin excretion after 8 weeks and significantly decreased extracellular matrix levels in db/db mice with diabetic nephropathy, showing more powerful renal protection than simvastatin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: